Monday, 25 February 2019

Medical Smart Textile Market to show steady growth, 2018

Market Scenario:
Smart fabrics and textiles are new fields of research, which have wide applications in healthcare. Sensors that are integrated into textiles and have contact with the body are able to capture physiological signals. Recently, medical engineering has brought a revolution in the field of medicine promoting new methods for the treatment and diagnosis of diseases. The demand for medical sensors and monitoring devices, evolving methods of diagnosis, increasing burden of diseases, and extensive use of wearable medical devices are driving the growth of this market. The higher cost of smart textiles acts as a restraint for this market. The global market for medical smart textiles is expected to register a CAGR of approximately 9.5% during the forecast period 2018–2027.


Segmentation
The Global Medical Smart Textile Market is segmented on the basis of technology, application, and end user.
By technology, the Global Medical Smart Textile Market is segmented into smart fabric technology, textile sensors, and wearable and joining technology.
By application, the Global Medical Smart Textile Market is segmented into surgery, hygiene, drug release systems, bio-monitoring, therapy, and wellness.
On the basis of end use, the Global Medical Smart Textile Market is segmented into hospitals, clinics, and others.
Key players
  • Google Inc. (US),
  • Intelligent Clothing Ltd. (UK),
  • International Fashion Machines (US),
  • Textronics, Inc. (US),
  • Interactivewear (Germany),
  • Sensoria Inc. (US), 
  • Schoeller Textiles AG (Switzerland),
  • Vista Medical Ltd. (Canada),
  • Gentherm (US).
Regional Market Summary
The medical smart textile market is dominated by North America owing to the extensive use of medical devices and applications in medical engineering for monitoring vital health indicators. It consists of two regions, namely, North America and South America. Most of the market players are engaged in continuous technological advancements in medical devices for ease of diagnosis, monitoring, and treatment.
It is estimated that Europe stood second in the global medical smart textile market. Rising government initiatives to promote the healthcare sector and increased adoption of research and development activities in the healthcare domain drive the market in this region. Moreover, the entry of market leaders into strategic partnerships and collaborations with the chemical industry contributes to the growth of the market in Europe.
Asia-Pacific is likely to witness growth in the medical smart textile market during the forecast period owing to the increasing number of healthcare organizations, increasing prevalence of diseases, extensive demand for advanced medical devices, and increasing applications of technology in the early diagnosis of diseases. Moreover, the increasing prevalence of geriatric population in the region influences the market growth. China, India, and Japan are the key market players in this region and Asia-Pacific is expected to be the fastest growing market for medical smart textiles.  
The Middle East and Africa holds the least share in the global medical smart textile market due to the presence of stringent government policies and poor economies.
Browse Complete 115 Pages Premium Research Report Enabled with 69 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/medical-smart-textile-market-1123


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Dental Consumables Market to Observe Significant Growth by 2018

Market Scenario:
Acknowledging the developments and accruals the market is enjoying currently, Market Research Future (MRFR) in its recently published study report asserts that the global dental consumables market will be valued at USD 28,345 MN by 2024, registering approximately 7 % CAGR during the forecast period (2016 – 2024). 
The Dental Consumables Market is growing pervasively mainly due to the technological advancements that took place in the dental industry. Although the integration of technology & consumables in dental practices goes back to decades, the uptake of consumables has been increasing over the past few years, and so is increasing the growth of the dental consumables market. Furthermore, factors such as the wide adoption of dental consumables along with the increasing geriatric populace, prevailing dental disorders and surgeries are driving the market growth.
The rapidly growing dental treatment market is stressing on the wide uptake of advanced dental consumables which, in turn, offers lucrative opportunities to the players of the market. The proliferation of the Internet and smart connected devices acts as a tailwind influencing the market growth positively. Simultaneously, the market penetration of smartphones is a key driving force behind the market increase.
Attributing to the augmented applications of these consumables in the related market to target more users for branding the solutions, products & services; uptake of dental consumables is estimated to upsurge in small and medium setups during the prognosticated period.
On the other hand, these dental consumables are costlier especially in developing and underdeveloped nations which in turn, is hampering the market growth in these regions restricting the uptake of consumables. Also, the operational complexities of these consumables may restrain the growth of this market.
Key Players:
Some of the leaders in the market include 3M, Septodont, Straumann, KERR Corporation, Henry Schein, GC orthodontics, Patterson Dental, EnvisionTEC, American Orthodontics, Dentsply Sirona, Planmeca OY, and Nobel Biocare (Part of Danaher Corporation).
Dental Consumables Market – Segments
MRFR has segmented the analysis into two key dynamics for the convenience of understanding;
By Type        : Dental Implants, Dental Prosthetics, Dental Restorative Materials, and Dental Regenerative Materials among others.
By Regions     :  North America, Europe, APAC and the Rest-of-the-World.
Global Dental Consumables Market – Regional Analysis
The European region leads the global dental consumables market with the largest share.  The market growth is majorly fostered by the increasing per capita healthcare expenditures led by the resurging economy and the proliferation of healthcare sector in the region. Also, factors such as well-spread awareness among people towards oral health, especially in countries such as the UK, Germany, and Italy support market growth at a large scale.
The North American region closely following the European market accounts for the second-largest market for dental consumables. The market growth attributes to the increasing digital advancement in medical technology. The growing market in the US, backed by the high healthcare expenditures especially into the dental segment majorly supports the market growth in the region. Additional factors such as the huge technological advancements and uptake is a dominant factor fostering the growth of the North American dental consumables market.
The dental consumables market in the Asia Pacific region is proliferating rapidly, emerging as a promising market, globally. The burgeoning dental treatment markets, especially in India & China, backed by the vast population and the large unmet clinical needs fuel the market growth in the region.
Besides, some of the APAC countries such as Thailand, Vietnam, and Malaysia are estimated to contribute to market growth during the review period significantly. Offering substantial growth opportunities with the increasing awareness towards new technologies in untapped markets; the Asia Pacific dental consumables market will grow with approximately 7 % CAGR during the estimated period (2016-2024). 
Browse Complete 110 Pages Premium Research Report Enabled with 113 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/dental-consumables-market-1806 
Global Dental Consumables Market – Competitive Analysis
Highly competitive dental consumables market appears to be fragmented owing to the presence of many large and small-scale players. These players are adopting the strategic initiatives for business expansion plans in the emerging markets. Key players are focusing on optimized situational awareness to ensure their mission success. Matured players are continually seeking expansion through various strategic initiatives such as M&A activities, collaboration & innovations.
Matured players invest in R&D activities increasingly. Key players possess state of the art facilities to develop cost-effective product portfolio and a stable marketing network which can help them to gain the leadership position in the market while marketers operating in the dental industry are focusing on inbound lead generation more than ever, instantiating ROI-oriented strategies that can pay off quickly.
Industry/ Innovation /Related News:
November 18, 2018 – Cantel Medical Corporation (US), a leading company involved in the production and selling of medical equipment announced that it intends to acquire Omnia (Italy), a leading seller of a variety of dental surgical consumables for up to USD 31.9 MN in total consideration to expand in the European markets.

         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Pacemaker Market - Granular Market Report and Review, 2018

The global pacemaker market is likely to post a CAGR of 6.5% over the forecast period of 2018-2023, asserts Market Research Future (MRFR) in an exclusive study. Surging prevalence of cardiovascular diseases across the globe is the prime drive behind the growth of the global pacemaker market. A pacemaker is used in the management of atrial fibrillation, to maintain adequate heart rate. Increasing global geriatric remains a significant growth driver. The old age population is more prone to developing cardiac disorders and subsequently boosting the growth of the global pacemaker market. Technological advancements in the pacemaker arena have resulted in the development of improved pacemakers with extended battery life, smaller size, better performance, and reduced failure rate. Leadless pacemakers are the new addition to the pacemaker space. They are typically the size of a pill and can be implanted with a minimally invasive procedure. Other driving factors include raising awareness regarding cardiovascular disorders and the general decline in the prices of pacemakers and treatment procedures. The rise in a number of FDA approval for new pacemakers can also be credited for the growth of the market. On the contrary, the growth of the global pacemaker market might be hindered due to the high costs associated with pacemakers which limit market growth in price-sensitive markets. Post-implantation complications of pacemakers are also possible bottlenecks to the growth of the global pacemaker market.  The market growth is also at a threat from alternative treatment options.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/1587
Competitive Landscape
The key players in the global pacemaker market include Biotronik GmbH & Co. KG (Germany), Medtronic Plc (U.S.), Sorin Group, St. Jude Medical Inc. (U.S.), Edwards Lifesciences (U.S.), ATS Medical (U.S.), Vitatron Holding B.V. (the Netherlands), Zoll Medical Corporation (U.S.), and Boston Scientific Corporation (U.S.).

Segmentation
The pacemaker market has been segmented based on product type, application, implant approach, and end user.

By product type, the global pacemaker market has been segmented into implantable, and external. The implantable segment has been segmented into single chamber, dual chamber, and biventricular.

By application, the global pacemaker market has been segmented into syncope, hypertrophic cardiomyopathy, bradycardia, and heart failure. The bradycardia segment has been further segmented into sinus node dysfunction and AV block.

By implant approach, the global pacemaker market has been segmented into endocardial approach and epicardial approach.

By end user, the global pacemaker market has been segmented into hospitals & clinics, ambulatory surgical centers, research & academic institutes, and others.

Regional Analysis
Geographically, the global pacemaker market has been segmented into the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).

The Americas pacemaker market has been segmented into North America and South America. The Americas is at the forefront of the global pacemaker market due to the high prevalence of cardiovascular disorders in the region which induces greater demand for pacemakers. The region tends to adopt advanced technologies swiftly which coupled with higher affordability drives the market in the Americas.

Europe is the second largest market for a pacemaker. The Europe market is driven by government funding for R&D and the presence of leading market participants in the regions. APAC is slated to be the fastest growing market over the forecast period. The MEA market is likely to exhibit the lowest growth due to limited development in the medical field, lack of technical knowledge, and poor medical facilities.

Industry Updates
December 2018- Carondelet St. Joseph’s Hospital in Tuscon, the US is now offering a leadless pacemaker which can be implanted through a minimally-invasive surgical procedure. The pacemaker can be used to treat patients with irregular or slower-than-normal heart rate. The new pacemaker is about the size of a vitamin pill and does not require cardiac wires.

Browse Complete 90 Pages Premium Research Report Enabled with 83 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/pacemaker-market-1587




       
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

ELISpot and FluoroSpot Assay Market 2018–By Identifying the Key Market Segments and Key players holding market share


ELISpot and FluoroSpot Assay are a sensitive technique used for the recognition of immune cells which specific proteins such as cytokines or antibodies. These asses are used in hospitals and research institutes for early diagnosis for diseases such as TB and other viral infection. The FluoroSpot assay is a modification of ELISpot in which combinations of monoclonal antibodies with different reagents are used to detect the infection. The key factor responsible for driving the market growth are increasing incidence of chronic diseases, rising vaccine development to solve the challenge of antimicrobial resistance, technological advancements in analyzers and ELISpot and FluoroSpot assay kits. However, the factors such as lack of skilled technicians, and alternative detection technologies may limit the market growth during the forecast period.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6948         
The Global ELISpot and FluoroSpot Assay Market were estimated USD 135 million in 2017 and expected to reach USD 287 million by 2023 at a CAGR of 16.2 % during the forecast period.
Key players:
Some of the key players in the global ELISpot and FluoroSpot Assay market are Oxford Immunotec (UK), Cellular Technologies (US), Mabtech (Sweden), Becton, Dickinson and Company (US), and Abcam (UK)Bio-Techne (US), Autoimmun Diagnostika (Germany), Biotech Investissement (France), Lophius Biosciences (Germany), and U-CyTech (Netherlands), and Others.
Segmentation:
The Global ELISpot and FluoroSpot Assay Market is segmented on the basis of product, application, and end-user. The ELISpot and FluoroSpot Assay market, by product is categorised into various assay kit, analyzer, ancillary products. The assay kit is sub-segmented into T Cell assay and B Cell assay. On the basis of application, the market is segmented into transplant, vaccines development, clinical trials, cancer treatment. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centres, diagnostic centres, research centers, and others.
On the basis of region, the Global ELISpot and FluoroSpot Assay Market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Regional Analysis:
Europe stood second largest in the ELISpot and FluoroSpot Assay market owing to the increasing number of pharmaceutical companies, rising in the development of innovative vaccines for the treatment of various viral diseases. The growing funding from government and private agencies for drug development also support the ELISpot and FluoroSpot Assay market in this region.  Asia-Pacific was estimated to be the fastest growing region for the global ELISpot and FluoroSpot Assay market in 2017. The market is expected to witness growth owing to the rising prevalence of viral infection, increasing geriatric population in this region and growing demand for ELISpot and FluoroSpot Assay in research field.
The Middle East and Africa holds the least share in the global ELISpot and FluoroSpot Assay market due to the presence of low health expenditure, lack of skilled technicians and less pharmaceutical company in this region. However, the market is expected to witness growth due to increasing research & development in the Middle East.

Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/elispot-and-fluorospot-assay-market-6948
    
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Ophthalmic Drugs Market 2018 - Opportunity, Driving Trends and deep study 2023

A number of factors such as rising prevalence of eye diseases, growing awareness, huge research funding in ophthalmology, unmet medical needs, rising competition among market players, improving regulatory framework, aging population, and increasing government assistance, are a few factors propelling the growth of the global ophthalmic drugs market. According to the 2017 statistics suggested by the World Health Organization (WHO), the chronic eye disease is the main cause of vision loss, globally.
Owing to the rising cases of eye diseases, the demand for an effective treatment option has also been escalating. In the recent years, various new and existing marketers have come up with effective drugs. For instance, in November 2017, Bausch & Lomb, a U.S.-based company, received the FDA approval for Vyzulta (latanoprostene bunod ophthalmic solution). The drug is designed for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.
However, the high cost associated with a diagnosis of eye diseases, side effects of available treatment options, and lack of healthcare insurance may hamper the growth of the market.
It is estimated that the ophthalmic drugs market is expected to grow at a CAGR 6.0% during the forecast period of 2017 to 2023.
Segmentation
The global ophthalmic drugs market is segmented on the basis of indication, drug class, type of dosage, product, distribution channel.
On the basis of indication, the market is classified as glaucoma, retinal disorders, inflammation/infection, dry eye, allergies, uveitis, and others.
On the basis of the drug class, the market is classified as antiallergy, anti-VEGF agents, anti-inflammatory, antiglaucoma, and others. The anti-inflammatory class is further segmented into nonsteroidal drugs and steroidal drugs.
On the basis of type of dosage, the market is classified as eye drops, eye solutions, ointments, capsules and tablets, and gels.
On the basis of the product, the market is classified as prescription drugs and OTC drugs.
On the basis of the distribution channel, the market is classified as hospital pharmacies, online pharmacies, drug stores, and others.
Regional Analysis
The Americas dominates the ophthalmic drugs market owing to the presence of patient population, rising prevalence of eye diseases, well-developed technology, high healthcare expenditure, and the presence of the leading players. According to the glaucoma research foundation, in the United States, more than 120,000 are blind because of glaucoma. This accounts for 9 to 12% of all the cases of blindness. It is also reported that over 3 million Americans have glaucoma, but only a few of them know they have it. It is also reported that glaucoma accounts for more than 10 million visits to physicians each year. In November 2017, Bausch & Lomb, a U.S.-based company, received the FDA approval for Vyzulta (latanoprostene bunod ophthalmic solution). The drug is designed for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. In December 2017, Rhopressa (netarsudil ophthalmic solution) by Aerie Pharmaceuticals has also received the FDA approval for the treatment of glaucoma or ocular hypertension.
Europe holds the second position in the ophthalmic drugs market. It is expected that the government support towards research and development expenditure, increasing competition among marketers, and amendments in reimbursement policies in healthcare are likely to drive the European market.
Asia Pacific is the fastest growing ophthalmic drugs market owing to a huge patient pool, increasing demand, and development in healthcare technology.
The Middle East and Africa hold the lowest share of the global ophthalmic drugs market due to low development, lack of technical knowledge, and poor medical facilities.
Key Players
Some of the key players in the global ophthalmic drugs market are Actavis Generics, Allergan Plc, Bausch & Lomb Inc., Genentech, Inc., Merck & Co., Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Shire Plc, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Inc., and others.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/ophthalmic-drugs-market-5753

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Friday, 22 February 2019

Evans Syndrome Market to Observe Significant Growth by 2018

Evans syndrome (ES), is an autoimmune disorder characterized by the subsequent or simultaneous development of autoimmune hemolytic anemia, and immune thrombocytopenia. It is classified as primary or secondary based on its association with others diseases, such as primary antiphospholipid syndrome, systemic lupus erythematous (SLE), Sjögren syndrome, Hodgkin lymphoma, IgA deficiency, and chronic lymphocytic leukemia.
According to the Centers for Disease Control & Prevention, autoimmune disorder is the third most common category of disease in the United States after heart disease and cancer. It is reported that it affects approximately 5%–8% of the population i.e. 14–22 million persons.
The severity and symptoms of Evans syndrome vary greatly from one person to another. Some patients with Evans syndrome may first show the high destruction of red blood cells (RBCs), known as anemia, and others may first show low levels of platelets, known as thrombocytopenia. Low levels of white blood cells (WBSs), known as neutropenia, is less common in individuals with Evans syndrome than thrombocytopenia or anemia.
Notably, growing public awareness is the key factor driving the Evans syndrome market. Nowadays, people are becoming more aware of the different types of autoimmune disorders. Government and other different organizations have started educating people about hygiene and diseases through seminars, and conferences. People are becoming more aware and conscious of the diseases. Thus, increasing awareness has provided a push to the growth of the market.
Various other factors such as increasing incidents of autoimmune disorders, increasing government assistance, improving regulatory framework, increasing automation of laboratories and rising funding and reimbursement are continuously contributing to the growth of the global Evans syndrome market.
Despite these drivers, there are some issues associated with Evans syndrome market. Some of the challenges in research and development, side-effects of treatment, the presence of misbranded and spurious drugs, and poor healthcare system in low and middle-income countries, may hinder the growth of the market to an extent.
It is estimated that the Evans syndrome market is expected to grow at a CAGR 10.2% during the forecast period of 2017-2023.
Key Players
Some of key the players in the global Evans syndrome market are Pfizer, Merck & Co., Sanofi, Astellas Pharma, Inc., GlaxoSmithKline plc, Novartis AG, Enzon Pharmaceuticals, Inc., Bayer AG, Sigma-Aldrich, Abbott Laboratories, Eli Lily and Company, BD, ChemoMetec A/S, and Others.
Segmentation
The global Evans syndrome market is segmented on the basis of diagnosis, treatment, and distribution channels.
On the basis of the diagnosis, the market is classified as blood test, bone marrow biopsy, antibody assays, computed tomography (CT) scan, flow cytometry of double-negative T cells, and others. The blood test is further segmented into complete blood count (CBC), and direct antiglobulin test.
On the basis of the treatment, the market is classified as pharmacologic therapy, splenectomy,
Biologic therapy, stem cell transplantation, and others. The pharmacologic therapy is further segmented into Prednisone and intravenous immunoglobulin (IVIg) therapy. The biologic therapy is segmented into Rituximab and others.
On the basis of the distribution channel, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.
Regional Analysis
The Americas dominate the Evans syndrome market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in the Evans syndrome market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive the market of Europe region.
Asia Pacific is the fastest growing Evans syndrome market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/evans-syndrome-market-5136   


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Uterine Sarcoma Market to Observe Significant Growth by 2018

Market Scenario:
Sarcomas are the tumours of the mesenchymal tissues like bone, muscle, connective tissue, cartilage and fat. Uterine sarcoma is a rare type of cancer which starts in the muscle and supporting tissues of the uterus. Exposure to the X-rays increases the risk for uterine sarcoma. Unusual vaginal bleeding, spotting, or discharge are some of the common symptoms for the disease. Increasing prevalence of the uterine sarcoma and growing female geriatric population are the major drivers for the market growth during the forecast period, 2017-2023. In 2017, according to the American Cancer Society, 4,910 new cases of uterine sarcomas were reported in the U.S. Moreover, according to the World Bank, the female population which aged over 65 years rose from 316.27 billion to 347.25 billion in 2016. Additionally, rising healthcare expenditures and increasing awareness regarding women health is expected to boost the market growth. However, high cost of treatment and related side effects are the factors that can restrain the market growth. Chemotherapy is extensively exploited for the therapeutics of the uterine sarcoma. Some of the side effects of the chemotherapy are inclusive of hair loss, anemia, reduced fertility, and others.
The market for global uterine sarcoma is expected to grow at an approximate CAGR of 8.5% from 2017 to 2023.

Key players
  • Pfizer Inc.
  • Intas Pharmaceuticals Ltd.
  • FMC Corporation
  • Sun Pharmaceutical Industries Ltd.
  • Johnson & Johnson Services, Inc.
  • General Electric Company
  • Koninklijke Philips N.V.
  • Siemens Healthcare Private Limited

Segmentation
The global uterine sarcoma market is segmented on the basis of type, diagnosis, treatment, and end user.
On the basis of the type, the market is segmented into uterine leiomyosarcoma (LMS), endometrial stromal sarcoma (ESS), undifferentiated sarcoma, and others.
On the basis of the diagnosis, the market is categorised into sampling & testing, imaging tests, and others. The sampling & testing segmented is sub-segmented into endometrial biopsy, dilation and curettage, cystoscopy and proctoscopy, and others. The imaging tests segment is sub segmented into transvaginal ultrasound, computed tomography, magnetic resonance imaging, positron emission tomography scan, and others.
On the basis of the treatment, the market is segmented into surgery, radiotherapy, chemotherapy, hormone therapy, and others. The surgery segment is sub-segmented into bilateral salpingo-oophorectomy, hysterectomy, and others. The chemotherapy segment is sub-segmented into dacarbazine, docetaxel, doxorubicin, and others. The hormone therapy segment is sub segmented into progestins, aromatase inhibitors, and others.
On the basis of end users, the market is segmented into hospitals & clinics, academic institutes research organization, and others.
Regional Analysis
America dominates the global uterine sarcoma market owing to increasing adoption of new technologies and huge patient population. Additionally, rising healthcare expenditure and presence of a developed healthcare sector within the region fuels the market growth.
Europe is the second largest market for uterine sarcoma owing to rising research and development in healthcare sector and huge patient population.  By region, Europe is divided into Western Europe and Eastern Europe. The presence of developed economies like France, Germany, Italy have made the Western Europe to lead the market within the region. On the other hand, Eastern Europe is the fastest growing region in Europe.
Asia Pacific region is also regarded to be the fastest growing market. Increasing awareness for women health and growing healthcare sector are the major drivers for the market growth within the region. Moreover, the presence of the developing countries like the India and China within the region fuels the market growth. According to the Indian Brand Equity Foundation in 2017, the Indian healthcare sector was one of the fastest growing industries in India and is expected to advance at a CAGR of 22.87% from 2015-2020.
The Middle East & Africa has the least share in the global uterine sarcoma market due to presence of poor economies and stringent government policies, especially in the African region. Majority of the market of Middle & Africa region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure by the presence of the economies like Saudi Arabia, Kuwait and Qatar within the region.
Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/uterine-sarcoma-market-5131

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Subscribe to: Posts (Atom)